Michigan is One State Where Medicaid Covers Biomarker Testing for Lung Cancer – Interview
Significant Advancements Achieved in the Fight Against Lung Cancer; We’re Not Done Yet!
New Campaign Aims to Help Ensure “No One Missed” in Receiving Critical Biomarker Testing for Most Common Type of Lung Cancer!
Despite expanded lung cancer screening guidelines,
accelerated progress in the treatment of lung cancer, and a continued increase in survival rates, lung cancer remains the leading cause of cancer death in the U.S.,2 Almost one-quarter of all cancer deaths are due to lung cancer – more than breast, prostate, and colorectal cancers combined.
Due to the complexities of lung cancer,
the adoption of personalized medicine is critical to ensuring people receive the right treatment for their specific type of cancer at the right time. However, many people with the most common type of lung cancer — non-small cell lung cancer (NSCLC) — are not receiving a fully informed diagnosis due to a lack of comprehensive biomarker testing that can help identify important characteristics about an individual’s cancer and more precisely inform treatment decisions.
LUNGevity Foundation, the nation’s leading lung cancer-focused non-profit,
recently launched No One Missed – a new campaign that aims to increase awareness of comprehensive biomarker testing and empower patients and caregivers to discuss testing with their doctor for a fully informed diagnosis. Comprehensive Biomarker testing can reveal vital information to help identify the appropriate individualized treatment plan for each NSCLC patient.4
Join me in a recent interview
with Dr. Jorge Gomez, medical director of the solid tumor oncology unit at Mount Sinai Hospital in New York, and Andrea Ferris, President and CEO of LUNGevity Foundation, as they discussed No One Missed and address:
Recent milestones that will help advance lung cancer care
- Nationwide call for every person diagnosed with NSCLC to receive comprehensive biomarker testing
- Vital information gathered through comprehensive biomarker testing and how it can inform treatment decisions
- 3 key steps for every person living with NSCLC and their caregivers: Talk, Test, Treat
View the entire interview here:
For more information, go to NoOneMissed.org
Bio-Andrea Ferris – President and CEO of LUNGevity Foundation
Andrea Ferris is President and CEO of LUNGevity Foundation, the nation’s leading lung cancer organization focused on improving outcomes for people with lung cancer, and a member of the Board of Directors. In her role, Andrea is responsible for setting and executing the strategic direction of the organization and its science programs. She resides in the D.C. metro area.
Bio–Dr. Jorge Gomez – Medical Oncologist
Jorge Gomez, M.D., is a medical oncologist who specializes in the treatment of thoracic cancers. After six years at Memorial Sloan-Kettering and five years at the University of Miami Cancer Center, Dr. Gomez came to the Icahn School of Medicine at Mount Sinai to help build the Thoracic Oncology program. His main interests are in the field of new therapeutics in patients with activating mutations
*Interview is courtesy: AstraZeneca
 US Preventive Services Task Force. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(10):962–970. doi:10.1001/jama.2021.1117
 American Cancer Society. Cancer Facts & Figures 2021. Atlanta: American Cancer Society; 2021
 American Cancer Society. What Is Lung Cancer? Atlanta: American Cancer Society; 2019
 Gierman HJ, Goldfarb S, Labrador M, et al. Genomic testing and treatment landscape in patients with advanced non-small cell lung cancer (aNSCLC) using real-world data from community oncology practices. J Clin Oncol. 2019;37(suppl; abstr 1585)